Mária Wagnerová

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Thomas Brodowicz, Maciej Krzakowski, Matjaž Zwitter et al. · Lung Cancer · 2006 · 323 citations

Medicine, Oncology, Pharmacology +13

Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial

Christoph Zielinski, S. Beslija, Zrinka Mršić-Krmpotić et al. · Journal of Clinical Oncology · 2005 · 63 citations · Full text

Medicine, Oncology, Pharmacology +14

Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study

W.W. ten Bokkel Huinink, Jozef Šufliarský, Willem M. Smit et al. · Journal of Clinical Oncology · 2009 · 48 citations

Pharmacy, Oncology, Pharmacology +17

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17